(62 days)
The Philips Fresco release 1, add-on to Philips Integris systems, is intended for use in a cardiovascular and vascular x-ray interventional application, viz. stent placing.
The Philips Fresco release 1 will produce an enhanced image of a deployed stent in a coronary artery. To do so, it finds the area of the stent in every image of the Fresco run by finding the radiopaque bullets on the stent delivery catheter. These areas are processed such that the final result over all run images, produces an improved image of the stent area, whereas the distracting peripheral image parts have been blurred.
This 510(k) summary for the Philips Fresco release 1 device does not contain the detailed information necessary to fully address all aspects of your request regarding acceptance criteria and a study proving device performance. The document focuses on demonstrating substantial equivalence to predicate devices rather than providing a standalone clinical study report.
However, based on the provided text, here's what can be extracted and what information is missing:
1. Table of Acceptance Criteria and Reported Device Performance
This information is not explicitly stated in the provided 510(k) summary. The document mentions that the device "will produce an enhanced image of a deployed stent" and "will improve the visualization of the stent," but it does not specify quantitative acceptance criteria (e.g., specific metrics for image quality improvement, sensitivity, specificity, etc.) nor does it report the device's performance against such criteria.
| Acceptance Criteria | Reported Device Performance |
|---|---|
| Not specified | Not specified |
2. Sample size used for the test set and the data provenance
This information is not provided in the 510(k) summary. There is no mention of a specific test set, its size, or the country of origin/retrospective/prospective nature of any data used for performance evaluation.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
This information is not provided in the 510(k) summary. No details about experts for ground truth establishment are mentioned.
4. Adjudication method for the test set
This information is not provided in the 510(k) summary. No adjudication method is described.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
There is no indication of an MRMC comparative effectiveness study in the provided text. The document describes the device as an "add-on" that "will improve the visualization," implying a technical enhancement rather than a study on human reader performance with and without the aid.
6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done
The document describes the device's function: "To do so, it finds the area of the stent in every image... These areas are processed such that the final result... produces an improved image of the stent area..." This description suggests that the device's core functionality is indeed standalone image processing. However, a formal "standalone performance study" with specific metrics (e.g., how well the algorithm identifies stent areas, how much contrast it adds, signal-to-noise ratio improvement) is not detailed or reported in this 510(k) summary. The claim is for "enhanced stent visibility," which is a qualitative improvement from the algorithm itself.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
This information is not provided in the 510(k) summary. Given the absence of a detailed study, there's no mention of how ground truth (e.g., true stent presence, accurate stent boundaries) might have been established.
8. The sample size for the training set
This information is not provided in the 510(k) summary. There is no mention of a training set as the device is described as an image processing system that finds and processes areas. While such systems are often developed using data, a formal training set size isn't specified in this document.
9. How the ground truth for the training set was established
This information is not provided in the 510(k) summary.
Summary of what is available from the document:
- Device Function: The Philips Fresco release 1 produces an enhanced image of a deployed stent by finding the stent area through radiopaque markers and processing these areas to improve stent visualization while blurring peripheral distractions.
- Purpose: To improve stent visualization ("enhanced stent visibility") compared to basic stent visibility.
- Regulatory Pathway: 510(k) substantial equivalence to predicate devices (Philips diagnostic X-ray systems Integris H5000, Integris Allura, and Integris Allura Flat Detector).
- Safety and Effectiveness Justification: Compliance with applicable 21CFR requirements (Subchapter J - Radiological Health), UL 60950, and ACR/NEMA DICOM standard. The document states it "does not introduce new indications for use, nor does the use of the device result in any new potential hazard."
Conclusion:
The provided 510(k) summary is a regulatory document focused on demonstrating substantial equivalence. It describes the device's intended function and general safety/effectiveness through compliance with standards and comparison to predicate devices. It does not include the detailed performance study, acceptance criteria, sample sizes, or ground truth establishment methods that would be found in a comprehensive clinical or technical performance report for a newly developed device requiring such evidence.
{0}------------------------------------------------
Ko3 1836
Image /page/0/Picture/1 description: The image shows the Philips logo, which is a shield-shaped emblem. The word "PHILIPS" is written in bold, sans-serif font at the top of the shield. Below the text, there is a circular design featuring wavy lines and star-like shapes. The logo is presented in black and white.
AUG 1 4 2003
Philips Medical Systems
510(k) SUMMARY
The following information is being submitted in accordance with the requirements of 21 CFR 807.92.
| Company Name:Address: | Philips Medical Systems North America Company22100 Bothell Everett HighwayP.O.Box 3003Bothell, WA 98041-3003, USA |
|---|---|
| Registration No.: | 1217116 |
| Contact Person:Telephone No.: | Lynn Harmer(425) 487-7312 |
| Date Prepared: | June 12, 2003 |
| Device (Trade) Name: | Philips Fresco release 1 |
| Classification Name: | Image processing system, Class II, LLZI, 892.2050 |
Predicate Device:
The Philips diagnostic X-ray systems Integris H5000 (K984545), Integris Allura (K002016) and the Integris Allura Flat Detector (K031333) systems have the ability to visualize the stent. (basic stent visibility). Philips Fresco release 1, as an add-on to these systems, will improve the visualization of the stent (enhanced stent visibility)
Device description:
The Philips Fresco release 1 will produce an enhanced image of a deployed stent in a coronary artery. To do so, it finds the area of the stent in every image of the Fresco run by finding the radiopaque bullets on the stent delivery catheter. These areas are processed such that the final result over all run images, produces an improved image of the stent area, whereas the distracting peripheral image parts have been blurred.
Indications for Use:
The Philips Fresco release 1, add-on to Philips Integris systems, is intended for use in a cardiovascular and vascular x-ray interventional application, viz. stent placing.
{1}------------------------------------------------
510(k) Summarv Philips Fresco, release 1 Page 2 of 2
General Safety and Effectiveness
The device and the labeling will comply with the applicable requirements of 21CFR. Subchapter J - Radiological Health, parts 1020.10 and 1040.10 The device will comply with applicable requirements of the Underwriters Laboratories Standard for Safety UL 60950 and be classified by Underwriters Laboratories. The Philips Fresco release 1 will also comply with the ACR/NEMA DICOM digital imaging communication standard.
Conclusion:
The Philips Fresco release 1 does not introduce new indications for use, nor does the use of the device result in any new potential hazard.
Philips Medical Systems considers the Philips Fresco release 1 to be substantially equivalent with the predicate devices.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES. U.S.A." around the edge. Inside the circle is a stylized eagle-like symbol with three curved lines representing its body and wings. The seal appears to be a logo or emblem, possibly representing a government agency related to health and human services.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
AUG 1 4 2003
Ms. Lynn Harmer Manager, Regulatory Submissions Philips Medical Systems North America Company 22100 Bothell Everett Highway P.O. Box 3003 BOTHELL WA 98041-3003
Re: K031836
Trade/Device Name: Philips Fresco release 1 Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system
Regulatory Class: II Product Code: 90 LLZ Dated: June 12, 2003 Received: June 13, 2003
Dear Ms. Harmer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:
| 8xx.1xxx | (301) 594-4591 |
|---|---|
| 876.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4616 |
| 884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx | (301) 594-4616 |
| 892.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4654 |
| Other | (301) 594-4692 |
Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Nancy C. Brogdon
Nancy C. Brogdon Director, Division of Reproductive, Abdominal and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use statement
510(k) Number (if known):
Philips Fresco release 1 Device Name:
Indications for Use:
The Philips Fresco release 1, option to Philips Integris Allura systems, is intended for use in a cardiovascular and vascular x-ray interventional application, viz. stent placing.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED )
川 【NCCDCD 】 Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use .. (Per 21 CFR 801.109)
OR
Over-The-Counter Use .......
David A. Lyman
(Division Sign-Off) Division of Reproductive, Abdominal. and Radiological Devices 510(k) Number ________________________________________________________________________________________________________________________________________________________________
(Division Sign-Off)
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).